Dimitrios Papadopoulos
Associate Professor, Neurology
22559410
School of Medicine
Department of Medicine
Qualification | Year | Awarding Institution | Department |
PhD | 2003 | Imperial College London | Cellular and Molecular Neuroscience |
FEBN | 2012 | Union of European Medical Specialties (UEMS) | European Board of Neurology |
DIC | 2004 | Imperial College London | Cellular and Molecular Neuroscience |
MD | 1998 | National and Kapodistrian University of Athens | School of Medicine |
Period of employment | Employer | Location | Position | |
From | To | |||
2016 | To date | Hellenic Pasteur Institute | Athens | Research Associate |
2014 | To date | National and Kapodistrian University of Athens | Athens | Research Associate |
2006 | 2008 | Imperial College London | London | Research Fellow |
Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
2022 | Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms. | Choi S, Hill D, Guo L, Nicholas R, Papadopoulos D, Cordeiro MF. | Science Reports | 12 | 1806 |
2022 | Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. | Papadopoulos D, Gklinos P, Psarros G, Drellia K, Delicha EM, Friede T, Mitsikostas DD, Nicholas RS. | Journal of Neurology | e-pub ahead of print | |
2021 | Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. | Stanulović V, Hodolic M, Mitsikostas DD, Papadopoulos D. | British Journal of Clinical Pharmacology | 88 | 551 |
2021 | Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. | Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. | Cephalalgia | 41 | 851 |
2021 | Monoclonal Antibodies as Neurological Therapeutics. | Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. | Pharmaceuticals | 14 | 92 |
2021 | A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. | Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, Gourgioti R, Mitsias P. | Advances in Therapeutics | 38 | 1536 |
2020 | Aging, Cellular Senescence, and Progressive Multiple Sclerosis. | Papadopoulos D, Magliozzi R, Mitsikostas DD, Gorgoulis VG, Nicholas RS. | Frontiers in Cellular Neuroscience | 14 | 178 |
2012 | TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE | Tsakiri N, Papadopoulos D, Denis MC, Mitsikostas DD, Kollias G. | European Journal of Immunology | 42 | 403 |
2009 | Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. | Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R. | Brain Pathology | 19 | 238 |
2006 | Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. | Papadopoulos D, Ewans L, Pham-Dinh D, Knott J, Reynolds R. | Molecular Cellular Neuroscience | 31 | 597 |
Date | Title | Funded by | Project Role* | |
2018-2019 | Is cellular senescence responsible for disability progression in progressive multiple sclerosis? | Multiple society of Great Britain and Northern Ireland | Co-investigator | |
2017-2019 | The role of cellular senescence and ageing in disability progression in multiple sclerosis | Multiple Sclerosis Trials Collaboration, UK | Principal investigator | |
2020-to date | A non-interventional prospective observational study to assess the effect of treatment with dimethyl-fumarate on the change of cervical spinal cord load and cervical cord atrophy in Multiple Sclerosis patients | Genesis Pharma | Principal investigator | |
2017-2019 | Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis (FAMILY). A phase IV, non-interventional, observational multi-centre study. | Genesis Pharma | Principal Investigator | |
2006-2008 | A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) in Patients With Relapsing-remitting Multiple Sclerosis. | Novartis | Investigator | |
1999-2003 | Axonal loss and neurodegeneration in the Mog-induced EAE model of multiple sclerosis | NATO scholarship | PhD studentship |